In 112 patients with active noninfectious nonanterior uveitis, adalimumab and tocilizumab gave similar response at week 16 (16% vs 14%; mean difference -2.0%, CrI -16.8% to 12.3%); anakinra was stopped as ineffective at interim analysis.
RCTn = 112
Saadoun et al. Adalimumab, Anakinra, and Tocilizumab in Patients With Noninfectious Uveitis: A Multicenter Randomized Controlled Trial